Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PPOX | P50336 | 3/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19179848 | 0.94 | CCNE2 (0.41) | CCNE2CCNE1CDK2PIK3CAPIK3CG | |
| SCHEMBL18167004 | 0.83 | CCNE2 (0.36) | CCNE2CCNE1CDK2PIK3CAPIK3CG | |
| SCHEMBL873455 | 0.73 | HSP90AB1 (0.38) | CCNE1CDK2CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL15661443 | 0.72 | HTT (0.40) | CYP4F2CYP4A11MAPTSMN1; SMN2HSP90AB1 | |
| SCHEMBL12617050 | 0.67 | HDAC1 (0.53) | MAPTLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL21366512 | 0.66 | MITF (0.42) | CYP4F2CYP4A11MAPTLMNASMN1; SMN2 | |
| SCHEMBL17109715 | 0.66 | PIK3CG (0.36) | CCNE2CCNE1CDK2PIK3CAPIK3CG | |
| SCHEMBL13561299 | 0.66 | PIK3CG (0.36) | CCNE2CCNE1CDK2PIK3CAPIK3CG | |
| SCHEMBL17507861 | 0.65 | CYP4F2 (0.44) | CYP4F2CYP4A11LMNASMN1; SMN2HSP90AB1 | |
| SCHEMBL17581887 | 0.65 | HSP90AB1 (0.50) | CYP4F2CYP4A11MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340322-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | CCNE2 712/4885CCNE1 1174/4885CDK2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.